Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 25.65 [1][5]. Core Insights - The company reported a revenue of RMB 11.001 billion for 2025, a slight year-over-year decline of 1.88%, while the net profit attributable to the parent company was RMB 1.647 billion, reflecting a year-over-year increase of 1.18%. The non-recurring net profit was RMB 1.568 billion, up 9.50% year-over-year, aligning with consensus forecasts [5][6]. - Despite a slight decline in revenue, profit growth remains robust due to several factors, including stabilization in demand for infusion products and growth in specialized treatment areas. The company has focused on cost control, enhancing overall operational efficiency [5][6]. - Looking ahead to 2026, the company anticipates steady profit growth driven by stabilized demand for large-volume infusions and the expansion of specialized treatment areas benefiting from the company's channel advantages [5][6]. Revenue and Profit Forecast - Revenue projections for the company are as follows: RMB 11.676 billion in 2026 (up 6.14%), RMB 12.323 billion in 2027 (up 5.54%), and RMB 12.766 billion in 2028 (up 3.60%) [4]. - The net profit attributable to the parent company is expected to reach RMB 1.771 billion in 2026 (up 7.54%), RMB 1.907 billion in 2027 (up 7.68%), and RMB 2.050 billion in 2028 (up 7.51%) [4]. Segment Performance - The non-infusion segment generated revenue of RMB 8.348 billion in 2025, with growth in chronic disease and specialty areas. Chronic disease products are expected to stabilize as the impact of centralized procurement diminishes, while specialty areas are projected to continue growing [6][7]. - The infusion segment saw a revenue decline to RMB 2.533 billion in 2025, down 16.85% year-over-year, but is expected to stabilize in 2026 through strategic adjustments and new product introductions [7]. R&D and Innovation - The company is building a robust pipeline of innovative drugs, with 15 projects in development, including significant advancements in small molecule and nucleic acid drug technologies. Recent acquisitions and collaborations are expected to enhance its market position in key therapeutic areas [8][9]. Valuation Metrics - The company is projected to have a PE ratio of 15 times for 2026, with a target price of RMB 25.65, reflecting a narrowing discount compared to previous valuations [9].

Core Viewpoint - The company reported a slight decline in revenue and net profit for Q1 2025, primarily due to high base effects and weakened demand in the large infusion segment, but maintains a positive outlook for steady profit growth in 2025 driven by product upgrades and new market explorations [1][2]. Group 1: Financial Performance - Q1 2025 revenue reached 3.079 billion yuan, a year-over-year decrease of 2.10%, with net profit attributable to shareholders at 507 million yuan, down 1.26% year-over-year [1]. - The large infusion segment saw a revenue decline of 16% year-over-year, totaling 770 million yuan, attributed to high base effects and seasonal demand fluctuations [1]. - Non-infusion segment revenue for Q1 2025 was 2.28 billion yuan, reflecting a year-over-year increase of 3.35%, driven by growth in gynecology and oncology specialties [2]. Group 2: Segment Analysis - The large infusion segment is expected to stabilize in sales volume, with ongoing upgrades in packaging and production efficiency to maintain profit levels despite revenue declines [1]. - The non-infusion segment's growth is supported by steady performance in chronic disease treatments and strong sales in specialty areas, particularly gynecology and oncology [2]. - The raw materials segment experienced an 8.7% year-over-year revenue decline, but is anticipated to recover due to new product introductions and improved sales volumes [2]. Group 3: Growth Potential - The company has established eight core technology platforms and is advancing over 20 key projects, indicating a robust pipeline for future growth [2]. - Expansion into e-commerce and OTC channels is expected to contribute to a targeted revenue growth of 10% in 2025 [2]. - New product launches, including innovative drugs for diabetes and antiviral treatments, are projected to drive revenue growth, supported by a strong sales team [2]. Group 4: Profit Forecast and Valuation - The company forecasts EPS of 1.69, 1.83, and 1.96 yuan for 2025, 2026, and 2027 respectively, with a target price of 27.04 yuan based on a 16x PE ratio for 2025 [3].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of 27.04 RMB [7][8]. Core Views - The company reported Q1 2025 revenue of 3.079 billion RMB (down 2.10% year-on-year) and a net profit of 507 million RMB (down 1.26% year-on-year), primarily due to a high base in the large infusion segment and weakening demand [1]. - Despite a slight decline in the large infusion segment, the company is expected to see steady net profit growth in 2025, driven by packaging upgrades and an increase in the proportion of nutritional and therapeutic infusions [1][4]. - The non-infusion segment showed robust growth, with Q1 2025 revenue of 2.28 billion RMB (up 3.35% year-on-year), supported by steady performance in chronic disease products and strong growth in specialty areas like gynecology and oncology [3]. Summary by Sections Infusion Segment - Q1 2025 revenue for the infusion segment was 770 million RMB (down 16% year-on-year), affected by high base effects and seasonal demand fluctuations [2]. - The company anticipates a slight decline in revenue for the large infusion segment but expects to maintain profit levels through cost reductions via packaging upgrades and automation [2]. Non-Infusion Segment - The non-infusion segment's revenue growth is driven by chronic disease products and specialty areas, with a 15% year-on-year increase in the specialty segment due to the launch of new oncology products [3]. - The raw material drug segment experienced an 8.7% year-on-year decline, but the company expects recovery in 2025 due to new product launches and improved sales [3]. Potential Growth Points - The company has established eight core technology platforms and has over 20 core projects in development, indicating a strong pipeline for future growth [4]. - The expansion into e-commerce and OTC channels is expected to contribute to a 10% revenue growth target for 2025 [4]. Profit Forecast and Valuation - The company’s EPS is projected to be 1.69 RMB for 2025, with a PE ratio of 16 times, aligning with the industry average [5][6]. - The revenue forecast for 2025 is 11.605 billion RMB, reflecting a growth rate of 3.51% [6].